Fibrocell Science Inc (FCSC) Sees Large Increase in Short Interest

Fibrocell Science Inc (NASDAQ:FCSC) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,083,658 shares, a growth of 43.3% from the October 31st total of 756,335 shares. Based on an average daily trading volume, of 116,142 shares, the short-interest ratio is currently 9.3 days. Approximately 11.9% of the company’s shares are sold short.

Shares of Fibrocell Science (FCSC) opened at $1.37 on Monday. Fibrocell Science has a 52 week low of $1.32 and a 52 week high of $4.64.

Several research firms have recently commented on FCSC. Zacks Investment Research raised Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. HC Wainwright set a $6.00 price objective on Fibrocell Science and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 price objective (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. Finally, ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Fibrocell Science presently has a consensus rating of “Hold” and a consensus target price of $5.21.

Institutional investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC grew its stake in shares of Fibrocell Science by 264.0% during the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after purchasing an additional 35,000 shares during the period. Creative Planning grew its stake in shares of Fibrocell Science by 395.3% during the second quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after purchasing an additional 48,755 shares during the period. Finally, Pura Vida Investments LLC acquired a new stake in shares of Fibrocell Science during the third quarter worth $909,000. 55.81% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Fibrocell Science Inc (FCSC) Sees Large Increase in Short Interest” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/04/fibrocell-science-inc-fcsc-sees-large-increase-in-short-interest.html.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

What are top analysts saying about Fibrocell Science Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit